SAN DIEGO, CA, Feb. 22, 2021 (GLOBE NEWSWIRE) — via NewMediaWire – Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary Kannaway® has submitted its Novel Foods application for its cannabidiol (CBD) products to the UK’s Food Standards Agency (FSA) through the European Industrial Hemp Association (EIHA) Novel Foods Consortium.
“We are witnessing a pivotal moment in history when the global appetite for free access to CBD for all people is very high,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We see this in the US with many recent positive discussions among US congressional officials to pass legislation for federal legalization of cannabis but also new bills for CBD to be regulated as a dietary supplement and food ingredient. In the United Kingdom, there are measures to secure that market’s unity, safety and efficacy for the sale of CBD. With regard to Europe, we could not be more excited to continue the push for free access to all.”
The EIHA Novel Food Consortium, formed in June 2020, allows Kannaway® to strengthen its commitment to provide free access to CBD-based products throughout the EU. Now that the application has been submitted to the FSA, the next step is to undertake the submission to the European Food Safety Authority (EFSA).
“It is very encouraging to see the industry’s leading companies banding together to ensure free access,” said Kannaway® Managing Director of International Janne Heimonen. “We appreciate the EIHA and its other members for their unified efforts to bear the costs for the necessary toxicological studies and additional approval procedures.”
Kannaway® is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway® currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products.
About Medical Marijuana, Inc.
We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Neuropathix, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.
Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.’s corporate video, click here.
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
Public Relations Contact:
Investor Relations Contact:
P. (858) 283-4016